Literature DB >> 6993038

Is there a role for radiotherapy in localized diffuse lymphomas?

T P Miller, S E Jones.   

Abstract

Entities:  

Mesh：

Year:  1980        PMID： 6993038     DOI： 10.1007/bf00254024

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  18 in total

1.  No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types.

Authors:  C S Portlock; S A Rosenberg
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

2.  Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases.

Authors:  S E Jones; Z Fuks; M Bull; M E Kadin; R F Dorfman; H S Kaplan; S A Rosenberg; H Kim
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

3.  Non-Hodgkin's lymphomas. V. Results of radiotherapy.

Authors:  S E Jones; Z Fuks; H S Kaplan; S A Rosenberg
Journal:  Cancer       Date:  1973-09       Impact factor: 6.860

4.  Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma.

Authors:  M G Chen; L R Prosnitz; A Gonzalez-Serva; D B Fischer
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

5.  Chemotherapy of localised histiocytic lymphoma.

Authors:  T P Miller; S E Jones
Journal:  Lancet       Date:  1979-02-17       Impact factor: 79.321

6.  Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.

Authors:  E M McKelvey; J A Gottlieb; H E Wilson; A Haut; R W Talley; R Stephens; M Lane; J F Gamble; S E Jones; P N Grozea; J Gutterman; C Coltman; T E Moon
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

7.  Survival of patients with localized histiocytic lymphoma.

Authors:  J D Bitran; J Kinzie; D L Sweet; D Variakojis; M L Griem; H M Golomb; J B Miller; N Oetzel; J E Ultmann
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

8.  CVP-remission-maintenance in stage I or II non-Hodgkin's lymphomas: preliminary results of a randomized study.

Authors:  T G Landberg; L G Håkansson; T R Möller; W K Mattsson; K E Landys; B G Johansson; D C Killander; B F Molin; P F Westling; P H Lenner; O G Dahl
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

9.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

Authors:  P S Schein; V T DeVita; S Hubbard; B A Chabner; G P Canellos; C Berard; R C Young
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

10.  Curative radiotherapy for localized diffuse histiocytic lymphoma.

Authors:  S H Levitt; C D Bloomfield; G Frizzera; C K Lee
Journal:  Cancer Treat Rep       Date:  1980-01
View more
  3 in total

Review 1.  Combined chemotherapy plus radiotherapy for treatment of early-stage intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  J H Briggs; T P Miller
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

2.  Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy.

Authors:  B Vaughan Hudson; G Vaughan Hudson; K A MacLennan; L Anderson; D C Linch
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

3.  A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).

Authors:  Mi Joo Chung; Won Kyung Cho; Dongryul Oh; Keun-Yong Eom; Jin Hee Kim; Woo Chul Kim; Jong Hoon Lee
Journal:  J Radiat Res       Date:  2019-10-23       Impact factor: 2.724
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.